预约演示
Bayer ends respiratory distress drug development in latest phase 2 cleanout
2023-08-08
临床2期临床3期临床失败临床1期
It was not until May that Bayer decided “not to pursue further development activities” for adrenomedullin pegol.
Bayer has dropped an acuteBayeriratory distress syndrome drug in phase 2 development for “sadrenomedullin pegolthe German pharma giant revealed in its latest earnings results.
Bayerompany “decided acute respiratory distress syndromectivities” for the drug, called adrenomedullin pegol, in May, Bayer said in this morning’s second-quarter earnings release (PDF). Adrenomedullin is a human hormone that is involved in vasodilation, among other activities.
A phase 2 trial of the inhaled formulation wrapped up at the end of last year, accordingadrenomedullin pegolov. While Bayer only alluded to “scientific reasons” as the cause of its decision, a note attached to the trials register said the study was terminated due to the results of part A of the trial and “not due to any safety data.”
It was not until May that the company decided “not to pursue further development activities” for adrenomedullin pegol,Bayerr added.
Picking out some other notable pipeline developments over the first half of the year, Bayer used adrenomedullin pegol rBayerrm two previously disclosed phase 2 pipeline culls. The company explained that a decision was made in April to halt work on runcaciguat, a soluble guanylate cyclase (sGC) activator that was being developed for chronic kidney disease (CKD).
Bayer didn’t give a reason for the decision, but did point out that it hasn’t given upBayerts sGC program entirely. The company is still pushing ahead with another sGC activator called BAY3283142. The oral therapy, which is currently in a phase 1 truncaciguatD, isoluble guanylate cyclase (sGC) activatorsoluble guanylate cyclase (sGC)follow-up” therapy to runcaciguat, with chronic kidney disease (CKD)roved pharmacokinetic/pharmacodynamic profile.”
Bayerly, the company explained that a BDKRB1 receptor antagonist was benched because of the results of a phase 2a trial in neuropathic pain.sGC activatorBAY3283142CKDBayerruncaciguat
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。